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Abstract
Background: The human body exhibits a variety of biological rhythms. There are patterns that
correspond, among others, to the daily wake/sleep cycle, a yearly seasonal cycle and, in women,
the menstrual cycle. Sine/cosine functions are often used to model biological patterns for
continuous data, but this model is not appropriate for analysis of biological rhythms in failure time
data.
Methods: We adapt the cosinor method to the proportional hazards model and present a method
to provide an estimate and confidence interval of the time when the minimum hazard is achieved.
We then apply this model to data taken from a clinical trial of adjuvant of pre-menopausal breast
cancer patients.
Results: The application of this technique to the breast cancer data revealed that the optimal day
for pre-resection incisional or excisional biopsy of 28-day cycle (i. e. the day associated with the
lowest recurrence rate) is day 8 with 95% confidence interval of 4–12 days. We found that older
age, fewer positive nodes, smaller tumor size, and experimental treatment were predictive of
longer relapse-free survival.
Conclusion: In this paper we have described a method for modeling failure time data with an
underlying biological rhythm. The advantage of adapting a cosinor model to proportional hazards
model is its ability to model right censored data. We have presented a method to provide an
estimate and confidence interval of the day in the menstrual cycle where the minimum hazard is
achieved. This method is not limited to breast cancer data, and may be applied to any biological
rhythms linked to right censored data.
Background
The human body exhibits a variety of biological rhythms.
There are patterns that correspond, among others, to the
daily wake/sleep cycle, a yearly seasonal cycle and, in
women, the menstrual cycle. The clinical relevance of cir-
cadian rhythm has been demonstrated in multi-center
randomized trials [1-5]. They have confirmed the clinical
findings that optimal timing of chemotherapy can lead to
decreased toxicity. Halberg et al. [6] suggested a putative
benefit from timing nutriceuticals for preventive or cura-
tive health care.
Various mathematical models have been used to assess
the suitability of periodic functions associated with bio-
logical rhythms. The most common approach is that of
"cosinor rhythmometry", in which a linear least squares
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regression is used to fit a sinusoidal curve to time-series
data [7-10]. Tong [7] described the polar coordinate trans-
formation by which the sinusoidal regression problem
can be treated as a linear regression problem. Ware and
Bowden [8] suggested applying Rao's growth curve analy-
sis to distinguish between inter-and intra-subject vari-
ances to draw conclusions about population parameters.
Nelson et al [9] have provided a thorough review of calcu-
lations and analytic techniques including single, group,
and population statistics. Another suggested approach for
analysis has been to integrate the sinusoid to account for
differences between point- and time-averaged data [10].
Others have considered a nonparametric smooth curve
based on fitting a periodic spline function for human cir-
cadian rhythms [11,12]. These approaches, however, are
intended to study measurements over time from multiple
subjects to study the inherent dynamics of circadian
rhythms. Although these curve-fitting techniques can be
helpful, they are not suitable for right-censored failure
time data (FTD).
Failure may be broadly defined as the occurrence of a pre-
specified event. Events of this nature include time of
death, disease occurrence or recurrence and remission.
One important aspect of FTD is that the anticipated event
may not occur for each individual under study. This situ-
ation is referred to as censoring and the study subject for
which no failure time is available is referred to as cen-
sored. Censored data analysis requires special methods to
compensate for the information lost by not knowing the
time of failure of all individuals. The literature is short of
methodologies that deal with circadian or biological
rhythms in failure time data.
This article models the biological rhythms in censored
data. It presents a method to estimate the time that
achieves the minimum hazard along with its associated
confidence interval. The model is then used to predict the
optimal day in the menstrual cycle for breast cancer sur-
gery (i.e. day associated with the lowest recurrence rate) in
pre-menopausal women using data from the National
Cancer Institute of Canada's Clinical Trial Group MA.5
study.
Methods
The Model
The most common approach to the analysis of biological
rhythm is that of "cosinor rhythmometry" (see Nelson et
al. [9]). Cosinor analysis involves representation of data
span by the best-fitting cosine function of the form:
f(ti) = M + Acos(ωti + φ) + εi   (1)
where ti represents the time of measurements for the ith
individual, M the mean level (termed mesor) of the cosine
curve, A is the amplitude of the function, ω is the angular
frequency (period) of the curve, and φ is the acrophase
(horizontal shift) of the curve. It is assumed that the
errors, εi, are independent and normally distributed with
means zero and a common residual variance σ2. It is also
possible to use more than one cosine function with differ-
ent values of ω (whether or not in harmonic relation) or a
combined linear-nonlinear rhythmometry [13,14]. The
equation can be fitted to the data by conventional meth-
ods of least-squares regression analysis. Obviously, this
assumption will not hold for failure time data with
skewed and censored observations.
The Cox regression model (proportional hazard model)
[15] is the appropriate method for regression analysis of
survival data. This model is frequently used to estimate
the effect of one or more covariates on a failure time dis-
tribution. Let XT = (X1, ..., Xp) denote p measured covari-
ates on a given individual with censored failure time
observation. Then the proportional hazards model can be
written as
where λ0(t) is a baseline hazard corresponding to XT = (0,
..., 0), βT = (β1, ..., βp) is a vector of regression coefficients,
and  βTX is an inner product. The important inference
questions in this setting are about the conditional distri-
bution of failure, given the covariates. In order to examine
the effect of biological rhythm upon survival, one needs to
adapt cosinor rhythmometry to the proportional hazard
model.
Let us assume that we have n independent individuals (i =
1, . . . n). For each individual i, the survival data consist of
the time of the event or the time of censoring ξi, an indi-
cator variable, δi, with a value of 1 if ξi is uncensored or a
value of 0 if ξi is censored, and Xi = [X1i X2i]T, so that the
observed data are (ξi, δi, Xi). Here X1i = cosωti, X2i = sinωti
and ω = 2π/τ. Hence β1 = A cosφ and β2 = - A sinφ. The
angular frequency (ω) must be set based on our knowl-
edge of the pattern; this is often based on 24 hours but can
be different values for different individuals.
The proportional hazards model (2) for the ith of n indi-
viduals can be re-expressed as:
λi(t) = λ0(t)exp(β1x1i + β2x2i)   (3)
This equation is almost the same as the cosinor equations
with the same meaning. We should notice that in this
model the effects are multiplicative instead of additive.
The mesor parameter M is taken up in λ0(t), and it is dif-
ficult to draw the cosine curve on top of the data as in the
continuous case.
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Parameter Estimation
The  β-coefficients in the proportional hazards model,
which are the unknown parameters in the model, can be
estimated using the method of partial maximum likelihood.
Let t1 < ... <tL denote the L ordered times of observed fail-
ures. Let (i) provide the case label for the individual fail-
ing at t0 so the covariates associated with the L failures are
X(1), ..., X(L) . The log partial likelihood is given by
where ℜi is the set of cases at risk at time ti. The efficient
score for β, Z(β) = ∂/∂β log L(β), is
Maximum partial likelihood estimates β are found by
solving the p simultaneous equations Z(β) = 0.
Let   and   be the partial likelihood estimates of β1
and β2 respectively. Then, the parameter estimates   can
be obtained by reconverting the estimated   and   as
. The variance of   can be obtained
using the delta method [16] and is shown to be:
An approximate (1 - α) 100% confidence interval is
, where Zα/2 is the (1 - α/2) 100% cut off
point of the standard normal distribution.
The estimation of the amplitude can be obtained by
. The asymptotic variance of   can also
be obtained using delta method and is shown to be:
An approximate (1 - α) 100% confidence interval is
.
Optimal Time and its Confidence Interval
Some may determine the optimal time by trying different
partitions to the data where the variation looks cyclical.
The simplest cyclical pattern is the sine wave with its asso-
ciated parameters of amplitude, mean level (mesor),
angle frequency, and phase angle (acrophase). This sec-
tion will establish and construct an estimate and confi-
dence interval of the day where the minimum hazard is
achieved. The objective is to locate the optimal time for
intervention, which is the time where the curve is at a min-
imum.
Since we know that cos π = -1, the optimum time must be
when π = ωt + ,  where  ω = 2π/τ. Hence,
The variance of   is
The asymptotic 95% confidence intervals will be based on
the standard errors using an assumption of normality
.
Bootstrapping also can be used to estimate the variability
of the estimated function, and to provide information on
whether certain features of the estimated function are true
features of the data or just random noise [17,18].
Motivating Application: Biological Timing of Breast 
Cancer Surgery
While seasonality affects us all, the menstrual cycle
directly affects about 52% of the world's inhabitants. Each
of the members of this small global majority spends about
half of her life participating regularly and continuously in
this powerful biological rhythm. Many diverse disease
activities have been demonstrated to be affected by this
cycle. Cancer is one of these [19-22]. It has been conjec-
tured that menstrual stage at time of resection might affect
breast cancer outcome. Recurrence of breast cancer disease
may be affected by timing the surgery in relation to the
menstrual cycle; therefore, the timing of surgery may be
an important element that affects breast cancer outcome
[23,24].
The timing of surgical intervention for breast cancer may
have an influence on the outcome of these interventions
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[25,26]. Some studies have shown that patients who have
surgery during the follicular phase (first 14 days of the
cycle) have a higher recurrence rate than those treated dur-
ing the luteal phase (second 14 days of the cycle). Other
studies have shown that patients having surgery during
the perimenstrual period (days 0–6 and 21–36) of the
menstrual cycle had a quadrupled risk of recurrence and
death compared with women operated upon during the
middle (days 7 to 20) of their menstrual cycle [27,28].
Badwe et al. [29] stratified patients into groups containing
patients whose LMP was 3–12 days before surgery and
those who were operated on at other times. In contrast
with other studies, they showed that overall and recur-
rence-free survivals were each enhanced for those who
were resected during the luteal phase. Moreover, even the
definitions of follicular and luteal phases were made
based on different criteria in different institutions. Any
time an article was published there, were subsequent let-
ters to the editor or articles presenting contradictory
results [30-32]. These discrepancies might be explained by
the limited reliability of the menstrual history data, and
the fact that these studies were retrospective. This has
stimulated our interest in developing a more rigorous
method to estimate the best time that can be recom-
mended for surgical intervention based on a prospective
study. The only way to really answer this question would
be to perform a randomized controlled clinical trial.
The MA.5 study was a multi-center clinical trial conducted
by the National Cancer Institute of Canada Clinical Trial
Group (NCIC CTG) [33]. There were 262 pre-menopausal
patients who had adequate data for LMP included in the
study. All of them were eligible for the study, had normal
menstruation, and regular period cycles (lasting between
21 and 35 days) [34]. The recurrence of breast cancer was
confirmed with clinical or pathologic assessment, or both.
Initial tumor size, status of the axillary lymph nodes, and
other prognostic factors were assessed clinically and path-
ologically. Disease-free months were calculated from date
of surgery to date of first relapse. The trial was activated
December 1, 1989 and closed to accrual on July 31, 1993.
The objective was to examine disease-free survival in rela-
tion to the timing of breast tumor excision during the
menstrual cycle.
All analyses were conducted with SAS Version 9.1 and S-
Plus for Windows Version 6.0. All tests were two-sided,
and a level of α = 0.05 was used to determine a significant
result. Product-limit survival curves were calculated by the
method of Kaplan-Meier. The Cox proportional hazards
model [15] was used to estimate the relative risk of relapse
associated with timing of diagnostic surgery.
Results
The smoothed plot of the proportion of patients who
relapsed (Figure 1) suggests that relapse is at a minimum
when the tumor was excised during the first 1/4 of the
menstrual cycle, gradually rising to a maximum during
the last 1/4 cycle.
Multivariate analyses using the Cox Proportional Hazards
model identified age, positive nodes, pathologic stage,
and experimental treatment as the most significant factors
related to disease free survival. The time of surgery within
the menstrual cycle was a significant independent predic-
tor of disease-free survival.
Assuming that the length of the cycle is 28 days for all
women, and using back- transformation, we obtained the
acrophase .  Therefore,  the
minimum time of the curve is
. The variance was
estimated using equation (7) as 4.2 and hence the 95%
confidence interval lies between 4 and 12 days.
Using this optimal interval, the disease recurred in 55
patients (30%) in the group were LMP was 0–3 and 13–
40 days, whereas 10 patients (13%) developed disease in
mid-cycle (4–12 days) group. Figure 2 shows a statistical
significant difference in survival between these two groups
(p = 0.0084). After controlling for age, positive nodes,
pathologic stage, and arm, the menstrual phase at time of
excision remain significantly associated with relapse-free
survival (hazard ratio 0.425: CI. 0.214-0.845).
Since different comparisons had been made in the past
based on retrospective analyses, it was of interest to com-
pare results from approaches used in the past with the
approach proposed in this study:
Follicular vs. Luteal Stage Comparison
The risk for recurrence differed between the two phases:
30% of patients developed recurrence after surgery in the
luteal group compared with 20% in the follicular group.
Figure 3 indicates a higher recurrence rate for patients with
tumor excision during the luteal phase, but the differences
in survival were not statistically significant (P = 0.07).
However, after controlling for age, positive nodes, patho-
logic stage, and arm, the menstrual phase at time of exci-
sion was found to be significantly associated with relapse-
free survival (p = 0.011; hazard ratio 1.93: CI. 1.16 –
3.19).
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Mid-cycle vs. Perimenstrual Stage Comparison
In this kind of menstrual interval, tumor recurred in 29%
of Perimenstrual patients and in 20% of mid-cycle
patients. Figure 4 indicates statistically insignificant differ-
ence in time to first recurred by phase (P = 0. 062). Based
on Cox proportional hazards model, the time of surgery
Relapse-Free Survival by Timing of Surgery: Proposed Definition Figure 2
Relapse-Free Survival by Timing of Surgery: Proposed Definition.
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within the menstrual cycle is not an independent predic-
tor of disease-free survival, p = 0.321 (hazard ratio 0.768:
CI. 0.455 – 1.294).
Discussion and Conclusion
In this paper we have described a method for modeling
failure time data with an underlying biological rhythm.
The advantage of adapting a cosinor model to propor-
tional hazard model is its ability to model right censored
data. We have presented a method to provide an estimate
and confidence interval of the day where the minimum
hazard is achieved.
Relapse-Free Survival by Timing of Surgery: Hrushesky's Definition Figure 4
Relapse-Free Survival by Timing of Surgery: Hrushesky's Definition.
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Relapse-Free Survival by Timing of Surgery: Senie's Definition Figure 3
Relapse-Free Survival by Timing of Surgery: Senie's Definition.
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The application of this technique to breast cancer data
revealed that the optimal days for pre-resection incisional
or excisional biopsy of 28-day cycle (i. e. the days associ-
ated with the lowest recurrence rate) are days 4–12. This
represents the putative follicular phase for women with 28
to 36 day cycle duration and the luteal phase for those
with the usual cycle length between 21 and 28 days. This
is in agreement with the contention that disease recur-
rence and metastasis are more frequent and appear more
rapidly in women who have had their initial breast cancer
resection during days 0–6 and 21–36 of the menstrual
cycle.
Most of studies designed to assess the efficacy of breast
surgery in relation to the timing of the intervention during
the menstrual cycle were retrospective. This article
presents a prospective investigation of menstrual cycle
operative timing. The proposed analytical technique is
not limited to breast cancer data and may be applied to
any biological rhythms linked to right censored data.
Competing interests
We did not identify any situation that might be perceived
as a conflict of interest.
Authors' contributions
The authors contributed equally to this work.
References
1. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJ,
Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G,
Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J,
Cote C, Blanc C, Herait P, Bleiberg H: Clinical activity and benefit
of irinotecan (CPT-11) in patients with colorectal cancer
truly resistant to 5-fluorouracil (5-FU).  Eur J Cancer 1999,
35(1):54-59.
2. Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL,
Regensberg C, Vannetzel JM, Reinberg A, Mathe G: Chemotherapy
of advanced ovarian cancer with 4'-O-tetrahydropyranyl
doxorubicin and cisplatin: a randomized phase II trial with an
evaluation of circadian timing and dose-intensity.  J Clin Oncol
1990, 8(4):705-714.
3. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano
G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous
infusion of oxaliplatin at circadian rhythm-modulated rate
compared with constant rate.  J Natl Cancer Inst 1990,
82(12):1046-1050.
4. Depres-Brummer P, Levi F, Di Palma M, Beliard A, Lebon P, Marion
S, Jasmin C, Misset JL: A phase I trial of 21-day continuous
venous infusion of alpha-interferon at circadian rhythm
modulated rate in cancer patients.  J Immunother 1991,
10(6):440-447.
5. Depres-Brummer P, Berthault-Cvitkovic F, Levi F, Brienza S, Vannet-
zel JM, Jasmin C, Misset JL: Circadian rhythm-modulated (CRM)
chemotherapy of metastatic breast cancer with mitox-
antrone, 5-fluorouracil, and folinic acid: preliminary results
of a phase I trial.  J Infus Chemother 1995, 5(3 Suppl 1):144-147.
6. Halberg F, Cornelissen G, Wang Z, Wan C, Ulmer W, Katinas G,
Singh R, Singh RK, Singh RK, Gupta BD, Singh RB, Kumar A, Kanab-
rocki E, Sothern RB, Rao G, Bhatt ML, Srivastava M, Rai G, Singh S,
Pati AK, Nath P, Halberg F, Halberg J, Schwartzkopff O, Bakken E,
Governor Shri Vishnu Kant S: Chronomics: circadian and cir-
caseptan timing of radiotherapy, drugs, calories, perhaps
nutriceuticals and beyond.  J Exp Ther Oncol 2003, 3(5):223-260.
7. Tong YL: Parameter estimation in studying circadian
rhythms.  Biometrics 1976, 32(1):85-94.
8. Ware JH, Bowden RE: Circadian rhythm analysis when output
is collected at intervals.  Biometrics 1977, 33(3):566-571.
9. Nelson W, Tong YL, Lee JK, Halberg F: Methods for cosinor-
rhythmometry.  Chronobiologia 1979, 6(4):305-323.
10. Hickey DS, Kirkland JL, Lucas SB, Lye M: Analysis of circadian
rhythms by fitting a least squares sine curve.  Comput Biol Med
1984, 14(2):217-223.
11. Wang Y, Brown MB: A flexible model for human circadian
rhythms.  Biometrics 1996, 52(2):588-596.
12. Wang Y, Ke C, Brown MB: Shape-invariant modeling of circa-
dian rhythms with random effects and smoothing spline
ANOVA decompositions.  Biometrics 2003, 59(4):804-812.
13. Halberg F: Chronobiology: methodological problems.  Acta med
rom 1980, 18:399-440.
14. Cornelissen G, Halberg F: Chronomedicine.  In Encyclopedia of
Biostatistics Edited by: Armitage P, Colton T. Chicheter, UK , John
Wiley & Sons Ltd; 2005:796-812. 
15. Cox D: Regression Models and Life Tables.  Journal of the Royal
Statistical Society 1972, B34:187-220.
16. Kendall M, Stuart A: The advanced Theory of Statistics.  Volume
I. London , Griffin; 1986. 
17. Tibshirani R, Hastie T: Local likelihood estimation.  JASA 1987,
82:559-567.
18. Efron B: Computer-intensive methods in statistical regres-
sion.  SIAM Review 1988, 30:421-449.
19. Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ: Circa-
dian timing in cancer treatment: the biological foundation
for an integrative approach.  Integr Cancer Ther 2003,
2(2):105-111.
20. Levi F: Circadian chronotherapy for human cancers.  Lancet
Oncol 2001, 2(5):307-315.
21. Hrushesky WJ: Rhythmic menstrual cycle modulation of
breast cancer biology.  J Surg Oncol 2000, 74(3):238-241.
22. Wood PA, Hrushesky WJ: Circadian rhythms and cancer chem-
otherapy.  Crit Rev Eukaryot Gene Expr 1996, 6(4):299-343.
23. Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa P:
Menopausal status dependence of the timing of breast can-
cer recurrence after surgical removal of the primary
tumour.  Breast Cancer Res 2004, 6(6):R689-96.
24. Zurrida S, Galimberti V, Gibelli B, Luini A, Gianoglio S, Sandri MT, Pas-
serini R, Maisonneuve P, Zucali P, Jeronesi G, Pigatto F, Veronesi U:
Timing of breast cancer surgery in relation to the menstrual
cycle: an update of developments.  Crit Rev Oncol Hematol 2001,
38(3):223-230.
25. Saad Z, Bramwell V, Duff J, Girotti M, Jory T, Heathcote G, Turnbull
I, Garcia B, Stitt L: Timing of surgery in relation to the men-
strual cycle in premenopausal women with operable breast
cancer.  Br J Surg 1994, 81(2):217-220.
26. Senie RT, Rosen PP, Rhodes P, Lesser ML: Timing of breast cancer
excision during the menstrual cycle influences duration of
disease-free survival.  Ann Intern Med 1991, 115(5):337-342.
27. Hrushesky WJ, Bluming AZ, Gruber SA, Sothern RB: Menstrual
influence on surgical cure of breast cancer.  Lancet 1989,
2(8669):949-952.
28. Spratt JS, Zirnheld J, Yancey JM: Breast Cancer Detection Dem-
onstration Project data can determine whether the progno-
sis of breast cancer is affected by the time of surgery during
the menstrual cycle.  J Surg Oncol 1993, 53(1):4-9.
29. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE,
Rubens RD, Fentiman IS: Timing of surgery during menstrual
cycle and survival of premenopausal women with operable
breast cancer.  Lancet 1991, 337(8752):1261-1264.
30. Goldhirsch A, Gelber R, Forbes J: Timing breast cancer surgery.
Lancet 1991, 338(8768):691-693.
31. Nomura Y, Kataoka A, Tsutsui S, Murakami S, Takenaka Y: Lack of
correlation between timing of surgery in relation to the
menstrual cycle and prognosis of premenopausal patients
with early breast cancer.  Eur J Cancer 1999, 35(9):1326-1330.
32. Milella M, Nistico C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM,
Botti C, Giannarelli D, Lopez M, Cortesi E, Foggi CM, Antimi M, Ter-
zoli E, Cognetti F, Papaldo P: Breast cancer and timing of surgery
during menstrual cycle: a 5-year analysis of 248 premeno-
pausal women.  Breast Cancer Res Treat 1999, 55(3):259-266.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Circadian Rhythms 2006, 4:14 http://www.jcircadianrhythms.com/content/4/1/14
Page 8 of 8
(page number not for citation purposes)
33. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE,
Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A,
Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams
C, Tu D: Randomized trial of intensive cyclophosphamide,
epirubicin, and fluorouracil chemotherapy compared with
cyclophosphamide, methotrexate, and fluorouracil in pre-
menopausal women with node-positive breast cancer.  Journal
of Clinical Oncology 1998, 16(8):2651-2658.
34. Fehring RJ, Schneider M, Raviele K: Variability in the phases of the
menstrual cycle.  J Obstet Gynecol Neonatal Nurs 2006,
35(3):376-384.